CORONA Remedies on Thursday said it has acquired seven brands from the pharmaceutical division of Bayer in India for an undisclosed sum.
The acquisition includes brands in the cardiology segment (Noklot) and women’s healthcare portfolio (Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston) in the Indian market, the company said in a statement.
Through the acquisition, the company said it is entering the anti-platelet monotherapy segment while also increasing presence in the cardiology domain.
